Advertisement
U.S. markets closed
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,131.53
    +62.42 (+0.16%)
     
  • Nasdaq

    15,996.82
    -44.80 (-0.28%)
     
  • Russell 2000

    2,016.69
    +2.85 (+0.14%)
     
  • Crude Oil

    76.57
    -2.04 (-2.60%)
     
  • Gold

    2,045.80
    +15.10 (+0.74%)
     
  • Silver

    22.98
    +0.19 (+0.84%)
     
  • EUR/USD

    1.0823
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • GBP/USD

    1.2673
    +0.0015 (+0.12%)
     
  • USD/JPY

    150.4400
    -0.0600 (-0.04%)
     
  • Bitcoin USD

    51,059.84
    -139.07 (-0.27%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

Adalimumab Biosimilar Market is Probable to Influence the Value of USD 3431.48 Million by 2030, Size, Share, Trends, Growth and Competitive Outlook

Data Bridge Market Research
Data Bridge Market Research

Data Bridge Market Research analyses that the adalimumab biosimilar market which is USD 598.30 million in 2022, is expected to reach USD 3431.48 million by 2030, at a CAGR of 24.4% during the forecast period 2023 to 2030

HOUSTON, April 03, 2023 (GLOBE NEWSWIRE) -- Data Bridge Market Research has recently published comprehensive business research on "Adalimumab Biosimilar Market" includes historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry. Adalimumab Biosimilar Market research report is a demonstrated source of data and information that gives a telescopic view of the current market trends, situations, opportunities, and status. The report endows with the CAGR (compound annual growth rate) value fluctuations for the specific forecasted period which seems to be helpful in deciding costing and investment strategies. The market report is a specific study of the Adalimumab Biosimilar industry which explains the market definition, classifications, applications, engagements, and global industry trends. A brilliant team of analysts, experts, statisticians, forecasters, and economists has worked rigorously to generate this advanced and all-embracing Adalimumab Biosimilar Market research report.

Market information in the finest Adalimumab Biosimilar report analyses prime challenges faced by the Adalimumab Biosimilar industry currently and in the coming years, which gives an idea to other market participants about the problems they may face while operating in this market over a longer period of time. The report gives full knowledge about the market and competitive landscape which aids with enhanced decision-making, better managing the marketing of goods, and deciding market goals for enhanced profitability. Global Adalimumab Biosimilar Market research report also contains strategic profiling of major players in the market, meticulously analyzing their core competencies, and drawing a competitive landscape for the market.

Data Bridge Market Research analyses that the adalimumab biosimilar market which is USD 598.30 million in 2022, is expected to reach USD 3431.48 million by 2030, at a CAGR of 24.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Get a Sample PDF of the Adalimumab Biosimilar Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-adalimumab-biosimilar-market

Adalimumab, a monoclonal antibody, is used to treat autoimmune diseases such as rheumatoid arthritis and ulcerative colitis, among others. This medication helps to prevent future joint damage and maintain joint function by reducing joint swelling. As the global prevalence of arthritis rises, the market for adalimumab biosimilars is expected to grow during the forecast period.

According to GLOBOCAN 2020, there will be 2,281,658 new cancer cases and nearly 612,390 deaths in the United States in 2020. Furthermore, key market participants predicted market growth over the forecast period through various strategic activities such as product launches, mergers, and acquisitions. For instance, in July 2021, the FDA approved Viatris Inc.'s (formerly Mylan Pharmaceuticals Inc.) SEMGLEE (insulin-glargine-yfgn), a biosimilar to LANTUS (insulin glargine).

Competitive Landscape and Adalimumab Biosimilar Market Share Analysis

The adalimumab biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to adalimumab biosimilar market.

Some of the major players operating in the adalimumab biosimilar market are:

  • Alfred E. Tiefenbacher (GmbH & Co. KG) (Germany)

  • Amgen Inc. (U.S.)

  • Boehringer Ingelheim International GmbH (Germany)

  • Glenmark (India)

  • Zydus Group (India)

  • Torrent Pharmaceuticals Ltd. (India)

  • Reliance Life Sciences (India)

  • Emcure Pharmaceuticals Ltd (India)

  • Cipla Inc. (India)

  • Hetero (India)

  • AET BioTech (Germany)

  • Coherus Biosciences (U.S.)

  • Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan)

  • Momenta Pharmaceuticals (U.S.)

  • Oncobiologics (U.S.)

  • Pfizer Inc. (U.S.)

  • Samsung Bioepsis (South Korea)

  • Sandoz International GmbH (Switzerland)

Opportunities

  • Rising cancer cases

Cancer's growing burden and rising death toll necessitate the need for affordable treatment, boosting the growth of the biosimilar market. According to GLOBOCAN 2020, there will be 2,281,658 new cancer cases and nearly 612,390 deaths in the United States in 2020. Furthermore, key market participants predicted market growth during the forecast period through a variety of strategic activities such as product launches, mergers, and acquisitions. For instance, in July 2021, the FDA approved Viatris Inc.'s (formerly Mylan Pharmaceuticals Inc.) SEMGLEE (insulin-glargine-yfgn), a biosimilar to LANTUS (insulin glargine).

Download the Full PDF Research Report @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-adalimumab-biosimilar-market

Critical Insights Related to the adalimumab biosimilar Included in the Report:

  • Exclusive graphics and Illustrative SWOT analysis of some of the leading companies in this market

  • Value chain analysis of prominent players in the market

  • Current trends influencing the dynamics of this market across various geographies

  • Recent mergers, acquisitions, collaborations, and partnerships

  • Revenue growth of this industry over the forecast period

  • Marketing strategy study and growth trends

  • Growth driven factor analysis

  • Emerging recess segments and region-wise market

  • An empirical evaluation of the curve of this market

  • Ancient, Present, and Probable scope of the market from both prospect value and volume

Key Highlights from Adalimumab Biosimilar Market Study.

Revenue and Sales Estimation — Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry. Additionally, macroeconomic factor and regulatory policies are ascertained in Adalimumab Biosimilar industry evolution and predictive analysis.

Manufacturing Analysis — the report is currently analysed concerning various product type and application. The Adalimumab Biosimilar Market provides a chapter highlighting manufacturing process analysis validated via primary information collected through Industry experts and Key officials of profiled companies.

Competition — Leading players have been studied depending on their company profile, product portfolio, capacity, product/service price, sales, and cost/profit.

Demand & Supply and Effectiveness —Global Adalimumab Biosimilar report additionally provides distribution, Production, Consumption & EXIM** (Export & Import). ** If applicable

Drivers

  • Rise in biologic drugs

Several blockbuster biologic drugs from major pharmaceutical companies, including Truvada, Chantix, Forteo, Ciprodex, Afinitor, and many others, will lose US exclusivity in 2020. Several existing biological drugs, such as Erbitux, Avastin, and Orencia, will have their patents expire in the coming decade, providing an opportunity for many innovator companies as well as generic manufacturers to offer services specifically tailored toward biosimilars. Furthermore, the cost-effective nature of biosimilars, rising acceptance and adoption by various stakeholders, the need for diversification in technology and business models, and the growing prevalence of chronic diseases are expected to drive the global biosimilar market.

The investment made in the study would provide you access to information such as:

  • Adalimumab Biosimilar Market [Global – Broken-down into regions]

  • Regional level split [North America, Europe, Asia Pacific, South America, Middle East & Africa]

  • Country wise Market Size Split [of important countries with major market share]

  • Market Share and Revenue/Sales by leading players

  • Market Trends – Emerging Technologies/products/start-ups, PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, etc.

  • Market Size by application/industry verticals

  • Market Projections/Forecast

For A Deeper Understanding of the Market Analysis, Visit @ https://www.databridgemarketresearch.com/reports/global-adalimumab-biosimilar-market

Adalimumab Biosimilar Market Scope

Product

  • Exemptia

  • Adalirel

  • Cipleumab

  • Others

Distribution Channel

  • Hospitals Pharmacies

  • Retail Pharmacies

Adalimumab Biosimilar Market Regional Analysis/Insights

The Adalimumab Biosimilar Market is analyzed and market size insights and trends are provided by country, product and distribution channel as referenced above.

The countries covered in the adalimumab biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the adalimumab biosimilar market due to the proximity of multiple extensive experimentation laboratories.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the province's extensive commercial advancements and growing biotechnology corporations.

Table of Contents:

  1. Introduction

  2. Market Segmentation

  3. Executive Summary

  4. Premium Insights

  5. Global Adalimumab Biosimilar Market: Regulations

  6. Market Overview

  7. Global Adalimumab Biosimilar Market, By Product

  8. Global Adalimumab Biosimilar Market, By Distribution Channel

  9. Global Adalimumab Biosimilar Market, By Region

  10. Global Adalimumab Biosimilar Market: Company Landscape

  11. SWOT Analyses

  12. Company Profile

  13. Questionnaires

  14. Related Reports

To Access the Complete Table of Contents, Click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-adalimumab-biosimilar-market

Explore More Reports:

  • Biosimilar Market, By Product Type (Magnetic Resonance Imaging Scanners, Computed Tomography Scanners, Position Emission Tomography Scanners, Biosimilar (EEG), Electromyography Devices (EMG), Magnetoencphalography Devices, Transcranial Doppler Devices, Intracranial Pressure Monitors (ICP), Electrodes, Sensors, Gels and Cables), Drug Class (Insulin, Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Monoclonal Antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, Enoxaparin Sodium), Type of Manufacturing (In-House Manufacturing and Contract Manufacturing), Procedure (Invasive and Non-Invasive), Disease (Stroke, Dementia and Epilepsy), Indication (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Aortic Valve Stenosis and Others), Therapy Type (Oncology, Immunology, Haematology, Hormone Therapy, Metabolic Disorders, and Others), End Users (Hospitals, Clinics, Diagnostic Centres and Others) https://www.databridgemarketresearch.com/reports/global-biosimilar-market

  • Herceptin Biosimilars Market, By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lymphoma, Others), Dosage (150mg/single-dose vial, 420mg/multidose vial), End-Users (Specialty Clinics, Hospitals, Oncology Centers, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-herceptin-biosimilars-market

  • Clinical Trials Market, By Phase (Phase I, Phase II, Phase III, Phase IV), Indication (Autoimmune/Inflammation, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), Design (Interventional, Treatment Studies, Observational Studies, Expanded Access), End User (Hospital, Laboratories, Clinics), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-clinical-trials-market

  • Chilblains Treatment Market, By Symptom (Itching, Pain, Inflammation), Gender (Male, Female), Population at Risk (Smokers, Diabetic Patients, Patients Having Low BMI, Patients Suffering From Systemic Lupus Erythematosus, Others), Site (Fingers, Toes, Ear Lobes, Nose, Cheeks, Heels), Drug Type (Branded, Generic), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) https://www.databridgemarketresearch.com/reports/global-chilblains-treatment-market

  • At-Home Testing Kits Market, By Test Type (Pregnancy Test, HIV Test Kit, Diabetes, Infectious Diseases, Glucose Tests, Ovulation Predictor Test Kit, Drug Abuse Test Kit, and Others), Type (Cassette, Strip, Midstream, Test Panel, Dip Card and Others), Age (Pediatric, Adult and Geriatric), Sample Type (Urine, Blood, Saliva and Other Sample Types), Usage (Disposable and Reusable), Distribution Channels (Retail Pharmacies, Drug Store, Supermarket/Hypermarket and Online Pharmacies) https://www.databridgemarketresearch.com/reports/global-at-home-testing-kits-market

  • Arthritis Market, By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Rheumatoid Diagnosis (CRP Test, CCP, ESR Test), Osteoarthritis Type (Hip, Spinal, Knee, Foot and Ankle, Shoulder, Hand), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Route of Administration (Oral, Parenteral), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-arthritis-market

  • Aspirin Market, By Route of Administration (Oral, Rectal, Parenteral), Dosage Form (Tablets, Capsules, Injections, Suppositories), Applications (Pain, Fever and Inflammation, Deep Vein Thrombosis and Others), Dose Type (Adult Dose and Pediatric Dose), Availability (Prescription and OTC), Product Type (Alone and Combination Products), End User (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-aspirin-market

  • Injectable Drug Delivery Market, By Type (Injectable Drug Delivery Devices, Injectable Drug Delivery Formulation), Formulation Packaging (Ampoules, Vials, Cartridges, Bottles), Therapeutic Application (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Cancer, Others),  Usage Pattern (Curative Care, Immunization, Other), Site Of Administration (Skin, Circulatory/Musculoskeletal System, Organs, Central Nervous System), Distribution Channel (Hospital, Retail Pharmacy Stores), End User (Hospitals and Clinics, Home Care Settings, Others) https://www.databridgemarketresearch.com/reports/global-injectable-drug-delivery-market

  • North America Topical Drug Delivery Market, Product Type (Drug Delivery Formulations and Drug Delivery Devices), Delivery Techniques (Ionotophoresis, Sonophoresis, Laser Ablation, Radio Frequency Ablation, Magnetophoresis, Electroporation And Others), Type (Cleansing Agents, Protective Agents, Moisturizing Agents, Drying Agents, Anti-Itch Agents, Anti-Inflammatory Agents, Anti-Infective Agents, Keratolytics, and Others), Generation (First Generation Transdermal Delivery Systems, Second Generation Transdermal Delivery Systems and Third Generation Transdermal Delivery Systems), Mode of Purchase (Prescription and Over The Counter), Indication (Dermatological Disorders, Ophthalmic Disorders, Pain Management, Neurosurgical Disorders, Hormonal Therapy, Smoking Cessation and Others), Route of Administration (Dermal, Ophthalmic, Rectal, Vaginal, Nasal and Others), End User (Hospitals, Specialty Centers, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) https://www.databridgemarketresearch.com/reports/north-america-topical-drug-delivery-market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475

Email:- corporatesales@databridgemarketresearch.com


Advertisement